Table 3.
Risk factors associated with neutrophil recovery at day-28 and day-42 platelet recovery at day-90
| N1/N2 | Odds Ratio | p-value | |
|---|---|---|---|
| Neutrophil recovery at day-28 | |||
| Banking practice* | |||
| Group 1 | 92 /116 | 1.00 | |
| Group 2 | 188/270 | 0.54 (0.29 – 1.00) | 0.05 |
| Group 3 | 60/132 | 0.19 (0.08 – 0.44) | <0.001 |
| Age | |||
| ≤16 years | 269/412 | 1.00 | |
| >16 years | 71/106 | 2.01 (1.11 – 3.67) | 0.02 |
| Total nucleated cell dose | |||
| ≤ 3 × 107/kg | 31/58 | 1.00 | |
| > 3 – 5 | 89/140 | 1.65 (0.82 – 3.31) | 0.16 |
| > 5 | 220/320 | 3.26 (1.57 – 6.77) | 0.002 |
| Neutrophil recovery at day-42 | |||
| Group 1 | 104 /116 | 1.00 | |
| Group 2 | 225/270 | 0.61 (0.31 – 1.21) | 0.16 |
| Group 3 | 108/132 | 0.50 (0.23 – 1.06) | 0.07 |
| Total nucleated cell dose | |||
| ≤ 3 × 107/kg | 40/58 | 1.00 | |
| > 3 – 5 | 117/140 | 2.11 (1.03 – 4.33) | 0.04 |
| > 5 | 280/320 | 3.74 (1.90 – 7.35) | <0.001 |
| Conditioning regimen | |||
| TBI + cyclophosphamide | 327/379 | 1.00 | |
| Busulfan + cyclophosphamide | 110/139 | 0.52 (0.30 – 0.88) | 0.02 |
| Platelet recovery at day-90 | |||
| Group 1 | 76/116 | 1.00 | |
| Group 2 | 171/270 | 0.98 (0.61 – 1.58) | 0.93 |
| Group 3 | 69/132 | 0.61 (0.36 – 1.05) | 0.08 |
| Gender | |||
| Female | 145/260 | 1.00 | |
| Male | 171/258 | 1.58 (1.09 – 2.28) | 0.02 |
| Total nucleated cell dose | |||
| ≤ 3 × 107/kg | 23/58 | 1.00 | |
| > 3 – 5 | 88/140 | 2.43 (1.27 – 4.66) | 0.008 |
| > 5 | 205/320 | 2.64 (1.46 – 4.78) | 0.002 |
| Disease status | |||
| Early | 128/193 | 1.00 | |
| Intermediate | 141/222 | 0.82 (0.54 – 1.25) | 0.36 |
| Advanced | 47/103 | 0.45 (0.27 – 0.75) | 0.002 |
Odds ratios >1 indicate better outcome
N1 = number of events; N2 = number evaluable
TBI = total body irradiation
Other comparisons:
Day-28 neutrophil recovery:
Group 3 vs. Group 2, OR= 0.34 (0.16 – 0.74), p-value=0.04
Day-42 neutrophil recovery:
Group 3 vs. Group 2, OR=0.81 (0.47– 1.42), p-value= 0.46
Group 1 : automated processing, units were plasma and red blood cell reduced or buffy coat production method
Group 2 : manual processing, units were plasma and red blood cell reduced or buffy coat production method Group 3 : manual processing, units were plasma reduced
Early risk = patients in first complete remission / refractory anemia
Intermediate risk = patients in second complete remission
Advanced = patients in relapse / refractory anemia with excess blasts